GSK Investigational Site

Vero Beach, Florida 32960-6571

1 studies enrolling now · 22 studies all time

What they study most

Acute Coronary Syndrome, Asthma, Diabetes Mellitus, HIV Infection, HIV Infections, Human Immunodeficiency Virus Type 1 (HIV-1), Infection, Human Immunodeficiency Virus, Infection, Human Immunodeficiency Virus I, Pulmonary Disease, Chronic Obstructive, Rhinitis, Allergic, Perennial, Rhinitis, Vasomotor, Skin Infections, Bacterial

Studies at this site

• A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed — Recruiting now
• A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) — Running, not enrolling
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults — Running, not enrolling
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults — Running, not enrolling
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) — Completed
• A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants — Completed
• Dolutegravir Expanded Access Study — Completed
• Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects — Completed
• Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929) — Completed
• Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis — Completed
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) — Completed
• GW873140 In Combination With Combivir In HIV Infected Subjects — Stopped early
• Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA — Completed
• A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen — Completed
• Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL) — Completed
• A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR). — Completed
• Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults — Completed
• A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy — Completed